Background {#Sec1}
==========

Functional dyspepsia (FD) is a common condition in clinical practice \[[@CR1]\]. According to the Rome III and IV criteria, FD is defined as the presence of at least one of the following symptoms; postprandial fullness, early satiation, epigastric pain or burning, without evidence of structural disease to explain the symptoms fulfilling time criteria for the last three months with symptom onset at least six months before diagnosis and a frequency of at least three days per week \[[@CR2], [@CR3]\]. FD is subcategorized into two distinct conditions, which are postprandial distress syndrome, associated with meal-induced bothersome fullness or early satiation, and epigastric pain syndrome, showing bothersome epigastric pain or burning \[[@CR2], [@CR3]\].

This condition involves complex pathophysiologic mechanisms and shares overlapping symptoms with gastroesophageal reflux disease or other functional gastrointestinal disorders. The mainstay of the treatment of FD has been to target gastric acid secretion and impaired gut motility. The role of acid inhibitory drugs in the treatment of FD is well established \[[@CR4]\]. In a subtype of FD, the response rate of epigastric pain syndrome to acid inhibitory therapy is known to be better than that of post-prandial distress syndrome \[[@CR5]\].

Excluding acid inhibitory therapy, prokinetics are the mainstay of the treatment of FD. However, the role of prokinetics has not been well established, and inconsistent results have been reported regarding the therapeutic efficacy of each drug \[[@CR6]--[@CR10]\]. Moreover, previously published pairwise meta-analyses were conducted by examining several drugs with different mechanisms of action as a single group, which cannot present the efficacy of each prokinetic agent \[[@CR8], [@CR9]\]. However, head-to-head efficacy comparison of prokinetic agents in the treatment of FD is not easy and pooled comparative efficacy has not been established.

Unlike traditional pair-wise meta-analysis, network meta-analysis enables comparing more than 2 treatments strengthening the precision in the estimate and presenting relative effect sizes in a rank order \[[@CR11]\]. Therefore, this study aimed to evaluate the comparative effectiveness of each prokinetic in the treatment of FD using an indirect comparison method.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

A systematic review was conducted using electronic databases. MEDLINE (PubMed), EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library were searched using common keywords related to FD and prokinetics (inception to July 2015). The keywords were as follows: 'functional dyspepsia', 'prokinetics', 'mosapride', 'itopride', 'trimebutine', 'metoclopramide', 'domperidone', and 'acotiamide', drawn from MeSH or Emtree terminology and using Boolean operators. Only publications involving human subjects were searched. The bibliographies of relevant articles were also reviewed to identify additional studies. The language of publication was not restricted and all publications except Korean and English were translated using commercial translation service.

Selection criteria {#Sec4}
------------------

We included only randomized controlled trials (RCTs) meeting all of the following criteria: 1) designed to evaluate FD in the target or control group; 2) included a group that was given prokinetics and a comparison group that was given placebo or other prokinetics; and 3) presented comparative outcomes about symptomatic relief rates of FD after treatment. Exclusion criteria were as follows: 1) incomplete data or 2) review article.

Selection of relevant studies {#Sec5}
-----------------------------

Two of the authors (C.S.B. and G.H.B.) independently evaluated the eligibility of all studies retrieved from the databases based on the predetermined selection criteria. The abstracts of all identified studies were reviewed to exclude irrelevant articles. Full-text review was performed to determine whether the inclusion criteria were satisfied by the remaining studies. Disagreements between the two evaluators were resolved by discussion or by consultation with a third author (D.J.K.).

Assessment of methodological quality {#Sec6}
------------------------------------

The methodological quality of the enrolled studies was assessed using the Risk of Bias table (RoB). The RoB was assessed as described in the Cochrane handbook by recording the method used to generate the randomization sequence, allocation concealment, the determination of whether blinding was implemented for participants or staff, and whether there was evidence of selective reporting of the outcomes \[[@CR12]\]. Review Manager version 5.3.3 (Revman for Windows 7, the Nordic Cochrane Centre, Copenhagen, Denmark) was used to generate the RoB table. Two of the authors (C.S.B. and G.H.B.) independently evaluated the methodological quality of all studies, and any disagreements between the two evaluators were resolved by discussion or by consultation with a third author (D.J.K.).

Statistical analysis {#Sec7}
--------------------

We investigated the efficacy of prokinetics for the treatment of FD using odds ratios (ORs). We calculated the ORs based on an intention-to-treat analysis, when possible, from the original articles to compare the efficacy of prokinetics for the treatment of FD. Network meta-analyses were conducted using the Bayesian Markov Chain Monte Carlo method in WinBUGS 1.4.3 (MRC Biostatistics Unit, Cambridge, and Imperial College School of Medicine, London, UK) and Microsoft-Excel-based network meta-analysis tool (NetMetaXL) \[[@CR11]\]. Effect sizes for the Bayesian network meta-analysis were described with 95% credible interval. Statistical validity is guaranteed when the 95% credible interval does not include 1. The detailed data input form and initial data for the analysis of network meta-analysis can be found in the Additional file [1](#MOESM1){ref-type="media"}.

Results {#Sec8}
=======

Identification of relevant studies {#Sec9}
----------------------------------

Figure [1](#Fig1){ref-type="fig"} shows a flow diagram of how relevant studies were identified. A total of 946 articles were identified by searching 3 core databases and by hand searching the relevant bibliographies. In all, 307 duplicate articles and an additional 550 articles were excluded during the initial screening after reviewing the titles and abstracts. The full texts of the remaining 89 articles were thoroughly reviewed. Among these studies, 63 were excluded from the final analysis. The reasons for the exclusion of studies during the final review were as follows: review article (*n* = 19) or incomplete data (*n* = 45). The remaining 25 RCTs were included in the final analysis.Fig. 1Flow diagram for identification of relevant studies

Characteristics of studies included in the final analysis {#Sec10}
---------------------------------------------------------

In the 25 RCTs, we identified a total of 4473 participants (1602 placebo, 955 itopride, 773 domperidone, 713 acotiamide, 335 mosapride, 68 metoclopramide, and 27 trimebutine-treated participants). The enrolled studies were published between 1978 and 2012 \[[@CR13]--[@CR37]\]. All of the articles were full-text format except 2 studies \[[@CR13], [@CR36]\], which was in abstract format. More than half of the enrolled studies were conducted in Asia (*n* = 14) \[[@CR13]--[@CR26]\], followed by 9 studies in Europe \[[@CR27]--[@CR34]\], and the remaining 3 studies in the US \[[@CR35]--[@CR37]\]. Sixteen English-, 8 Chinese-, 1 Portuguese-, and 1 Korean-language studies were enrolled. The treatment duration ranged from 2 to 12 weeks. Eighteen studies used control medication as a placebo, whereas the remaining 8 studies performed direct head-to-head comparisons of prokinetic agents. All the prokinetic agents were orally administered and the detailed dosage, duration of prokinetics, and characteristics of the enrolled studies are shown in Table [1](#Tab1){ref-type="table"}.Table 1Clinical data of included studiesTreatment & studyLocation (language)Age (years)SexPlaceboItoprideMosaprideDomperidoneAcotiamideMetoclopramideTrimebutineDosage & treatment durationEffective/TotalEffective/TotalEffective/TotalEffective/TotalEffective/TotalEffective/TotalEffective/TotalVan Ganse W (1978)Belgium (English)mean 50 (range 24--82)M: 42 F: 31 (2 drop out)9/3631/3510 mg × 4/day, 2 weeksBekhti A (1979)Belgium (English)domperidone: median 43.5 (range 19--67), placebo: 47 (50--73)4/2013/2010 mg × 4/day, 4 weeksDe Loose F (1979)Belgium (English)median 40 (range 19--63)M: 16, F: 27 (multiphase study)22/7062/6810 mg × 4/day, 2 weeksDe Loose (1979)Belgium (English)median 40 (range 19--63)M: 16, F: 27 (multiphase study)22/7050/6810 mg × 4/day, 2 weeksVan Outryve M (1979)Belgium (English)domperidone: median 63 (range 32--80), placebo: 52 (25--81)M: 16, F: 2211/2213/1620 mg, × 3/day, 2 weeksVan de Mierop L (1979)Belgium (English)median 56 (range 32--76)M: 9, F: 232/1512/1710 mg, × 3/day, 4 weeksDavis RH (1988)US (English)mean 30 (range 18--48)M: 1, F: 153/77/920 mg, × 2/day, 6 weeksTeixeira CR (2000)Portugal (Portuguese)39 ± 13, (mean ± SD), (range 18--74)M: 19, F: 46 (22 cisapride allocated population)5/1618/27200 mg, × 3/day, 15 daysZhou LY (2000)China (Chinese)itopride: 42.6 ± 12.3, domperidone: 42.6 ± 12.8, (mean ± SD)Itopride; M: 34. F: 66, Domperidone; M: 38, F: 6379/10074/101itopride 50 mg, domperidone 10 mg × 3/day, 2 weeksHallerbäck BI (2002)Europe (multicenter) (English)range 18--75Mosapride; M: 49, F: 94, Placebo; M: 44, F: 9784/14184/14310 mg × 2/day, 6 weeksSun Jing (2003)China (Chinese)range 18--7058/11562/117itopride 50 mg, domperidone 10 mg × 3/day, 2 weeksMo Jian-zhong (2003)China (Chinese)mean 47.39 (range 21--70)M: 29, F: 5138/3929/40itopride 50 mg, domperidone 10 mg × 3/day, 2 weeksChen Xi (2004)China (Chinese)itopride: 34.7 ± 8.9, domperidone: 36.3 ± 11.1, (mean ± SD)17/2014/20itopride 50 mg, domperidone 10 mg × 3/day, 4 weeksAmaranpukar DN (2004)India (English)itopride: 45.23 ± 13.07, mosapride: 39.79 ± 10.82, (mean ± SD)M: 30, F: 3028/3019/30itopride 50 mg, mosapride 5 mg × 3/day, 2 weeksChen Shi-yao (2004)China (Chinese)mosapride: 44 ± 12, domperidone: 43 ± 13, (mean ± SD),M: 108, F: 123106/11892/113mosapride 5 mg, domperidone 10 mg × 3/day, 4 weeksZhu Chang-Qing (2005)China (Chinese)77/11973/117itopride 50 mg, domperidone 10 mg × 3/day, 4 weeksLi Yan-Hong (2005)China (Chinese)itopride: 38 ± 12, domperidone: 38 ± 12, (mean ± SD)M: 94, F: 10689/10089/100itopride 50 mg, domperidone 10 mg × 3/day, 4 weeksMatsueda K (2005)Japan (English)mean 3960% female21/3228/33100 mg × 3/day, 4 weeksHoltmann G (2006)Germany (English)47.9 ± 15.8, (mean ± SD)63.5% female56/13675/128100 mg × 3/day, 8 weeksTalley NJ (2008)US (English)35/10458/103200 mg × 3/day, 12 weeksTalley NJ (2008)US (English)itopride: 42.6 ± 12.8, placebo: 43.0 ± 12.5, (mean ± SD)Itopride: female 64.6%, placebo: female 69.8%112/316115/304100 mg × 3/day, 8 weeksLin Jinkun (2009)China (Chinese)range 19--65M: 20, F: 4012/3025/305 mg × 3/day, 2 weeksYeon-Mi Kim (2010)Korea (Korean)mosapride: 29.79 ± 7.56, placebo: 31.86 ± 11.53, (mean ± SD)M: 4, F: 245/1410/145 mg × 3/day, 2 weeksMatsueda K (2010)Japan (English)acotiamide: 37.5 ± 11.5, placebo: 37.3 ± 10.2, (mean ± SD)M: 100, F: 11143/10752/104100 mg × 3/day, 4 weeksKusunoki H (2012)Japan (English)acotiamide: 40.3 ± 13.2, placebo: 40.6 ± 13.0, (mean ± SD)M: 13, F: 24 (5 drop out)3/216/21100 mg × 3/day, 14--18 daysMatsueda K (2012)Japan (English)acotiamide: 37.6 ± 10.7, placebo: 37.1 ± 9.9, (mean ± SD)M: 363, F: 529 (5 drop out)154/445235/452100 mg × 3/day, 4 weeksTotal603/1602576/955244/335571/773379/71350/6818/27'Effective/Total' means number of symptom improved patients/total number of patients for given each prokinetic agent

Figure [2](#Fig2){ref-type="fig"} shows the network plot of relevant studies. Circles represent each prokinetic drug as a node and lines represent the direct comparisons. The extent of the circle indicates the number of included participants for each prokinetic drug, and the line thickness indicates the number of studies included in each comparison. Placebo was the biggest node, while the node size of metoclopramide and trimebutine was relatively smaller than the other remaining prokinetics. Direct comparisons were made between B (itopride) and D (domperidone) and between B (itopride) and C (mosapride). The remaining comparisons were performed in a pairwise manner.Fig. 2Network plot of relevant studies. Circles represent the each prokinetic drug as a node and lines represent the direct comparisons. The extent of circle indicates the number of included participants in each prokinetic drug and the line thickness indicates the number of studies included in each comparison

Comparative efficacy of prokinetics in FD {#Sec11}
-----------------------------------------

Figure [3](#Fig3){ref-type="fig"} shows the Forest plot of the results from a Bayesian network meta-analysis of the enrolled studies. The fixed-effect model was adopted based on the DIC statistics. The relative efficacy is plotted as OR with 95% credible interval. Based on these results, we calculated the surface under the cumulative ranking curve (SUCRA), which is the converted value reflecting the probability of a treatment being the best according to the ranking of each treatment \[[@CR11]\]. Table [2](#Tab2){ref-type="table"} shows the SUCRA of each treatment regimen. A higher SUCRA value indicates better therapeutic results based on the indirect comparison method \[[@CR38]\]. Metoclopramide showed the best SUCRA probability (92.5%), followed by trimebutine (74.5%), mosapride (63.3%), domperidone (62.9%), itopride (32.4%), acotiamide (24.3%), and placebo.Fig. 3Forest plot of enrolled studies. Forest plot shows relative effect of each prokinetic agent. Diamond is the summary estimate from the pooled studies with 95% Cr. Cr: credible interval Table 2SUCRA of each treatment regimenTreatment^a^SUCRAMetoclopramide0.925Trimebutine0.745Mosapride0.633Domperidone0.629Itopride0.324Acotiamide0.243Placebo0.002^a^SUCRA, surface under the cumulative ranking curve

However, the therapeutic efficacy of metoclopramide was not significantly different from that of trimebutine (OR: 1.32, 95% credible interval: 0.27--6.06), mosapride (OR: 1.99, 95% credible interval: 0.87--4.72), and domeperidone (OR: 2.04, 95% credible interval: 0.92--4.60) in the league table, which shows the relative efficacy using OR and 95% credible interval (Table [3](#Tab3){ref-type="table"}). Metoclopramide showed better efficacy than itopride (OR: 2.79, 95% credible interval: 1.29--6.21) and acotiamide (OR: 3.07, 95% credible interval: 1.43--6.75). Domperidone also showed better efficacy than itopride (OR: 1.37, 95% credible interval: 1.07--1.77) and acotiamide (OR: 1.51, 95% credible interval: 1.04--2.18).Table 3League table of each treatment regimenMetoclopramide1.32 (0.27--6.06)Trimebutine1.99 (0.87--4.72)1.51 (0.38--6.74)Mosapride2.04 (0.92--4.60)1.54 (0.40--6.73)1.02 (0.64--1.65)Domperidone2.79 (1.29--6.21)2.12 (0.56--9.05)1.40 (0.92--2.14)1.37 (1.07--1.77)Itopride3.07 (1.43--6.75)2.32 (0.61--9.86)1.53 (0.97--2.45)1.51 (1.04--2.18)1.10 (0.80--1.51)Itopride6.27 (3.03--13.48)4.77 (1.27--19.99)3.15 (2.09--4.74)3.15 (2.09--4.74)2.25 (1.78--2.85)2.05 (1.65--2.55)PlaceboOdds ratio with 95% credible interval is described in each column. Prokinetic agent in the top left means better efficacy and statistical validity is guaranteed when the 95% credible interval does not include 1

Figure [4](#Fig4){ref-type="fig"} shows the inconsistency plot of the enrolled studies. The plot demonstrates the posterior mean deviance of each study for the consistency model (horizontal axis), and the unrelated mean-effects model (vertical axis), along with the line of equality. There is some probability of inconsistency in the plot.Fig. 4Inconsistency plot of enrolled studies. Plot of the posterior mean deviance of each study for the consistency model (horizontal axis), and the unrelated mean-effects model (vertical axis), along with the line of equality

Adverse events related to prokinetics {#Sec12}
-------------------------------------

Adverse events related to prokinetics were as follows; domperidone induced diarrhea, constipation, intestinal colic, galactorrhea, bilateral breast tenderness, hyperprolactinemia, headache, dizziness, insomnia, and skin scare \[[@CR19], [@CR28], [@CR35]\]; mosapride induced diarrhea, constipation, abdomen pain, dry mouth, fatigue, dizziness, headache, leg pain, and nausea \[[@CR33]\]; itopride induced abdomen pain, diarrhea, constipation, nausea, and hyperprolactinemia \[[@CR34], [@CR38]\]; Acotiamide induced headache, diarrhea, increase in serum alanine aminotransferase, potassium, triglycerides, γ-glutamyltransferase, nasopharyngitis, and hyperprolactinemia \[[@CR24]--[@CR26]\]. Even control groups using placebo showed similar adverse events with treatment group taking prokinetics. Most adverse events were mild to moderate and have resolved after discontinuing prokinetics.

Methodological quality {#Sec13}
----------------------

For the methodological quality of enrolled studies, the exact determination of random sequence generation and allocation concealment was not available, and double-blinding was not consistent in all of the enrolled studies. The summary of the risk of bias is demonstrated in Fig. [5](#Fig5){ref-type="fig"}, and the risk of bias table of all enrolled studies is shown in Fig. [6](#Fig6){ref-type="fig"}.Fig. 5Summary of risk of bias. This figure summarizes the risk of bias for each study as a risk of bias summary of the overall meta-analysis. Green represents low risk of bias and red represents high risk of bias Fig. 6Risk of bias table of all enrolled studies. RoB, risk of bias. (+) denotes low risk of bias, blank denotes unclear risk of bias, (−) denotes high risk of bias

Discussion {#Sec14}
==========

FD involves complex pathophysiologic mechanisms including visceral hypersensitivity, impaired gastric accommodation, delayed gastric emptying, *H. pylori* infection, psychosocial disorders, and even an unhealthy lifestyle \[[@CR39]--[@CR41]\]. The prevalence of gastric emptying delay was reported to be 37--39% in patients with FD. Consequently, prokinetics were developed based on the concept that promoting impaired gut motility could reduce the symptoms of FD \[[@CR39], [@CR40]\]. However, improved delayed gastric emptying was not associated with symptomatic relief in patients with gastroparesis \[[@CR39], [@CR40]\]. It is apparent that dysmotility cannot be the only target. Multiple other mechanisms should be considered in the treatment of FD.

Proton-pump inhibitors (PPI) and prokinetic agents are the mainstays of the treatment of FD \[[@CR39]\], both of which have similar relative efficacy \[[@CR42]\]. However, adverse events related to PPI have been reported, and the comparative efficacy of prokinetics has thus far not been evaluated \[[@CR43], [@CR44]\]. Because the adverse events associated with PPIs are linked to long-term use of this medication and the recurrence of FD is not infrequent \[[@CR45]\], repeated prescriptions of PPI should be re-evaluated and additional focus should be directed toward the role of prokinetic agents in the treatment of FD.

In this analysis, the relative efficacy of prokinetics was based on the SUCRA value. However, there was no significant difference in efficacy between the prokinetics including metoclopramide, trimebutine, mosapride, and domperidone (Table [3](#Tab3){ref-type="table"}). Though the mechanisms of action of these medications are slightly different, the precise reason for the superior or inferior comparative efficacy between these medications could not be evaluated in this analysis. For example, although mosapride, itopride, and acotiamide are all known to modulate gastric accommodation, the statistical effects of these drugs differed in this analysis \[[@CR46]--[@CR48]\].

The frequency of adverse event must also be considered in selecting prokinetics for the treatment of FD. In the case of metoclopramide, which is a central D~1~ and D~2~ receptor antagonist, extrapyramidal symptoms including dystonic movement or tardive dyskinesia, which are often irreversible, inhibit the administration of high doses or the long-term use of this medication \[[@CR49]\].

In addition to the occurrence of adverse events, drug incompatibility due to drug interactions from a combination of prokinetics or other drugs should be considered in selecting prokinetics. Because domperidone, which is a peripheral D~2~ and D~3~ receptor antagonist is associated with ventricular arrhythmia, concomitant use of drugs that prolong the QTc interval, and potent CYP3A4 inhibitors should be avoided \[[@CR50]\].

With respect to serotonergic agonists, targeting multiple receptors with non-selective inhibition can potentially lead to adverse events. Cardiac arrhythmia or QTc prolongation was most commonly associated with cisapride and tegaserod \[[@CR51]\]. 5HT~1~ receptor subtypes have been suggested to account for adverse events due to interactions with HERG cardiac potassium channel and 5-hydroxytryptamine \[[@CR52]\]. Mosapride, which is a nonselective 5-HT~4~ agonist with no HERG or 5HT~1~ affinity, could be substituted for metoclopramide or domperidone for the specific subset of patients who need long-term treatment.

Trimebutine, which is an enkephalin agonist, has a dual action on both of hyperkinetic and hypokinetic motility disorders \[[@CR53]\]. This medication accelerates gastric emptying by inducing premature phase III activity of the migrating motor complex in gut \[[@CR9]\]. Although most studies are focused on the treatment of irritable bowel syndrome, this medication could be substituted for other prokinetics that potentially have serious adverse effects.

In this study, we could not investigate the reason for the relatively lower efficacy of itopride, a mixed D~2~ receptor antagonist, and acetylcholinesterase inhibitor or acotiamide, an M~1~/M~2~ muscarinic receptor antagonist and acetylcholinesterase inhibitor. Given the probability of inconsistencies in the enrolled studies and the superior efficacy of prokinetics that have a relatively small number of enrolled population, there could be an overestimation of efficacy drawn from the pairwise indirect comparison.

This study is the first meta-analysis evaluating the comparative effectiveness of prokinetic agents. The strength of this study is the rigorous searching of the literature without language limitations and the use of an indirect comparative method to address the challenge of performing head-to-head analyses in clinical practice. Nonetheless, there are several limitations that impact the generalizability of the main results. All of the available prokinetic drugs could not be included in this study. These omitted agents include levosulpiride, a selective D~2~ receptor antagonist, erythromycin, a motilin receptor agonist, tandospirone, a 5HT~1A~ agonist, prucalopride, a selective 5HT~4~ agonist or DA-9701, a 5HT~4~ agonist, D~2~ receptor and 5HT~3~ antagonist. These medications are not available in some countries. Furthermore, levosulpiride is associated with drug-induced parkinsonism, inhibiting its wide application in clinical practice \[[@CR54]\]. Prucalopride was developed and licensed for the treatment of constipation. Therefore, these drugs were excluded from the beginning of this study. Another limitation was the lack of data for some prokinetic agents in this analysis. The relatively small number of studies evaluating metoclopramide and trimebutine may in part explain the inconsistencies as well as the overestimation of the comparative effectiveness of some medications. In addition, most enrolled studies did not discriminate between epigastric pain and postprandial distress syndromes, which are subtypes of FD or post-infectious FD. Moreover, *H. pylori* infection, which is closely associated with the pathogenesis of FD, was not considered in most of the studies \[[@CR39]\]. Overlap syndrome (FD + gastroesophageal reflux disease or FD + irritable bowel syndrome) which is frequently encountered in clinical practice, was also not considered \[[@CR39]\]. A further limitation was the absence of a no common validated outcome measurement scale for all the enrolled studies. As we have noted in a previous study, there is no definite and unanimous way of defining symptomatic improvement in patients with FD \[[@CR6]\]. Further studies that include newer prokinetics and control for the above-mentioned limitations are needed to confirm the results of this study.

Conclusion {#Sec15}
==========

In conclusion, metoclopramide, trimebutine, mosapride, and domperidone showed better efficacy for the treatment of FD than that of itopride or acotiamide. Considering the adverse events related to metoclopramide or domperidone, the short-term use of these agents or the alternative use of trimebutine or mosapride could be recommended for the symptomatic relief of FD.

Additional file {#Sec16}
===============

Additional file 1:Contains tables for data input form and initial data for the analysis of network meta-analysis. (XLSX 17.6 kb)
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